Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | PTPRCAP | Q14761 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24622606 | 0.89 | PDK2 (0.43) | PDK2PGR | |
| SCHEMBL24622607 | 0.86 | PDK2 (0.38) | PDK2BACE1 | |
| SCHEMBL25452141 | 0.85 | PDK2 (0.50) | PDK2PGRPTPN11GABBR2GABBR1 | |
| SCHEMBL24728930 | 0.82 | PDK2 (0.37) | PDK2 | |
| SCHEMBL25896540 | 0.82 | AHR (0.31) | — | |
| SCHEMBL24618138 | 0.82 | PDK2 (0.31) | PDK2 | |
| SCHEMBL23395011 | 0.81 | PDK2 (0.32) | PDK2CTSD | |
| SCHEMBL23609507 | 0.81 | PDK2 (0.38) | PDK2 | |
| SCHEMBL24608815 | 0.81 | PDK2 (0.38) | PDK2BACE1 | |
| SCHEMBL23605801 | 0.81 | PDK2 (0.41) | PDK2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146030-A1 | ARYLAMINE COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146030-A1 | ARYLAMINE COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE | OCIAD2, AOC2, OCIAD1 | PDK2 1893/4885PGR 1516/4885PTPN11 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.